Shionogi Stock - Analyst consensus and sector context on a quiet news day
19.06.2026 - 19:10:44 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:05 UTC. Details in the imprint.
Shionogi (JP3347200002) is trading through the week without a fresh company announcement or major newsflash. With no new updates from investor relations or leading wire services, attention shifts to how the market values the Japanese drug maker versus peers and what analysts currently expect.
All news and data on Shionogi stock
Background information, historical news and further price data on Shionogi can be found via the dedicated topic page and the company's investor relations site.
What the consensus is saying
Recent data from MarketBeat show that the unsponsored ADR of Shionogi trades around $8.77 with a price-to-earnings ratio near 10.96 based on trailing earnings, giving the company a market capitalization of roughly $14.9 billion as of the latest close. MarketBeat provides the current ADR statistics.
According to the same dataset, Shionogi carries a consensus rating of "Buy" from covering analysts, while no single official price target is highlighted on that platform at the moment, underlining that coverage is comparatively thin for a Japan-based mid-to-large cap pharmaceutical name. The MarketBeat overview summarizes the rating.
How Shionogi sits in its peer group
Shionogi focuses on prescription drugs and vaccines and competes with other Japanese pharmaceutical groups such as Takeda Pharmaceutical and Astellas Pharma, which often command higher international visibility but operate with similar research-driven business models. Company information outlines Shionogi's positioning.
Against this backdrop, a price-to-earnings multiple just above 10 looks conservative compared with some global pharma majors that trade at mid-teens or higher earnings multiples, though direct comparisons must factor in pipeline risk, geographic mix and currency exposure.
The business behind the stock
Shionogi generates most of its revenue from research, development, manufacturing and marketing of branded prescription drugs, including anti-infectives, central nervous system therapies and metabolic drugs, alongside vaccines and contract development and manufacturing services for other pharmaceutical clients.
Where the stock trades today
The shares of Shionogi (JP3347200002) trade on the Tokyo Stock Exchange under the ticker 4507; the most recently available unsponsored ADR quote for SGIOY in the United States was $8.77 as of 06/18/2026, 15:59 Eastern Time.
Key facts on Shionogi stock
- Company: Shionogi & Co., Ltd.
- ISIN: JP3347200002
- WKN: 857035
- Ticker: 4507 (TSE), SGIOY (OTC US ADR)
- Venue: TSE, OTC US ADR
- Price (as of 06/18/2026, 15:59 Eastern Time): 8.77 USD (ADR)
- Market cap: 14.93 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: domestic Japanese indices; not a member of the Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
